Want to join the conversation?
$ALXN's Soliris (eculizumab) net product sales for 1Q16 grew to $665MM from $600MM in the previous year quarter. Net product sales grew 11% YoverY, despite continued currency headwinds as well as increased macroeconomic weakness in Latin American countries, primarily Brazil and Argentina. Soliris volume increased 18% YoverY.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.